The massive EPS beat and raised gross margin guidance, combined with the Sanofi Development Balance repayment that will structurally increase collaboration profits from Q3, create a strong positive catalyst. Monitor the Q3 2026 report for the first full quarter of post-repayment collaboration revenue and any updates on the cemdisiran PDUFA date in November 2026.
Drugs in focus
REGN drug pipeline →Otarmeni
● Neutral Named in this press release- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already FDA-approved (April 23, 2026); commercially available in the U.S.
- Next catalyst
- BLA filing · 2026
What to watchOtarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review) Named in filing
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion) Named in filing
- ● Evkeeza 4/10 Approved Named in filing
- ● EYLEA HD 4/10 Approved Named in filing
- ● Libtayo 4/10 Approved Named in filing
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 30 $738.34entry
- T+1 · 4mo ago +3.29%α +2.58% · $762.63
- T+5 · 3mo ago +4.57%α +0.95% · $772.11
- T+20 · 3mo ago +9.40%α +5.43% · $807.71
- T+60 · 25d ago +9.03%α +6.57% · $805.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% YoY), driven by strong Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%) sales. The Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3, and the company raised its full-year guidance on gross margins and narrowed R&D and SG&A ranges. The massive EPS beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $4.29B (+17% YoY), above $3.83B consensus
- Non-GAAP EPS $14.29 vs consensus $10.20 (+40.1% beat)
- GAAP EPS $12.23 (includes $1.02 negative IPR&D impact)
- Dupixent global net sales +38% to $6.0B; EYLEA HD U.S. +52% to $596M; Libtayo global +30% to $489M
- Sanofi Development Balance fully repaid as of Q2 end, boosting collaboration profits from Q3
- Full-year 2026 guidance: GAAP gross margin raised to 78-79% (from 77-78%); non-GAAP R&D narrowed to $5.95-6.05B; GAAP SG&A narrowed to $2.83-2.96B
- Share repurchases of $1.2B in Q2, $2.0B in H1 2026; $2.5B remaining under buyback programs
- Cemdisiran NDA accepted under FDA priority review for gMG with target action date Nov 2026
Financial Impact
Non-GAAP EPS beat consensus by 40.1% ($14.29 vs $10.20); revenue beat by $460M (12% above $3.83B consensus)
Risk Factors
- GAAP net income declined 7% YoY due to $127M IPR&D charge and higher tax rate (15.1% vs 8.4%)
- EYLEA franchise U.S. sales declined 12% YoY as EYLEA HD partially cannibalizes EYLEA
- Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
- Temporary manufacturing interruption at Limerick facility impacted Q2 gross margins (GAAP 78% vs 83% YoY)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335868 |
Track record
53 reports on REGN
10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers